# US 2008/0187546 A1 · Method for Replicating Influenza Virus in Culture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187546 A1
- Document ID: US20080187546A1
- Status: Published application
- Kind: A1
- Application number: 11/956,658
- Filed: 2007-12-14
- Published: 2008-08-07
- Earliest claimed: 2006-12-15
- Inventors: Terri L. Wasmoen; Peng Gao; Bradley Allen Eddy; Omar Yousif Abdelmagid
- Web page: https://patentgrep.com/patent/US20080187546A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/525: {Virus}
- C12N 2760/16151: Methods of production or purification of viral material
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.

## Claims

### Claim 1

A method of selecting a human influenza virus for growth on tissue culture cells by limiting dilution cloning, the method comprising:
serially diluting an influenza virus isolate and
contacting each dilution with cultured cells:
growing the cells for a time sufficient to produce cytopathic effects (CPE);
harvesting virus from the highest dilution that causes CPE; and
repeating the process with the harvested virus.

### Claim 2 (depends on 1)

The method of claim 1 further comprising admixing the influenza virus isolate with an effective amount of trypsin before contacting the cultured cells.

### Claim 3 (depends on 2)

The method of claim 2, wherein the trypsin is type IX trypsin.

### Claim 4 (depends on 2)

The method of claim 2, wherein the step of contacting the tissue-culture adapted isolate with the tissue culture cells is carried out at an MOI of less than about 0.01.

### Claim 5 (depends on 1)

The method of claim 1, wherein the tissue culture cells are mammalian embryonic kidney cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the mammalian embryonic kidney cells are human embryonic kidney cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the influenza virus is an influenza A, B, or C virus.

### Claim 8 (depends on 7)

The method of claim 7, wherein the influenza A virus is an H5N1 strain.

### Claim 9 (depends on 1)

The method of claim 1, wherein the influenza virus isolate is initially grown in embryonated eggs to obtain a large inoculum for adaptation to tissue culture.

### Claim 10 (depends on 9)

The method of claim 9, wherein the influenza virus isolate is initially grown on the amniotic membrane.

### Claim 11 (depends on 1)

A method for the production of a human influenza virus vaccine comprising purifying the harvested virus of claim 1.

### Claim 12 (depends on 11)

The method of claim 11, wherein the step of purifying is carried out using size exclusion chromatography.

### Claim 13 (depends on 11)

The method of claim 11, further comprising treating the virus with an amount of binary ethyleneimine (BEI) effective to inactivate the virus.

### Claim 14

An immunogenic composition comprising a BEI-inactivated human influenza virus and an adjuvant.

### Claim 15

A vaccine comprising a human influenza virus formulated at less than 4 μg of human influenza HA per dose wherein at least 70% of the HA has the same amino acid sequence.

### Claim 16 (depends on 15)

The vaccine of claim 15, wherein the human influenza virus is inactivated by BEI.

### Claim 17 (depends on 15)

The vaccine of claim 15, wherein the vaccine further comprises ISCOM.

### Claim 18 (depends on 15)

The vaccine of claim 15, wherein at least 90% of the HA has the same amino acid sequence.

### Claim 19

A method of selecting a canine influenza virus (CIV) H3N8 for growth on tissue culture cells by limiting dilution cloning, the method comprising:
serially diluting an influenza virus isolate and
contacting each dilution with cultured cells;
growing the cells for a time sufficient to produce cytopathic effects (CPE);
harvesting virus from the highest dilution that causes CPE; and
repeating the process with the harvested virus.

### Claim 20 (depends on 19)

The method of claim 19, further comprising admixing the influenza virus isolate with an effective amount of trypsin before contacting the cultured cells.

### Claim 21 (depends on 19)

the method of claim 19, wherein the trypsin is type IX trypsin.

### Claim 22 (depends on 19)

The method of claim 19, wherein the tissue culture cells are mammalian embryonic kidney cells.

### Claim 23 (depends on 5)

The method of claim 5, wherein the mammalian embryonic kidney cells are Madin-Darby bovine kidney (MDBK) cells.

### Claim 24

An immunogenic composition comprising an inactivated canine influenza virus (CIV) H3N8 and an adjuvant.

### Claim 25 (depends on 24)

The immunogenic composition of claim 24, wherein the adjuvant is an oil and water emulsion.

### Claim 26 (depends on 24)

The immunogenic composition of claim 24, wherein the adjuvant is aluminum hydroxide.

### Claim 27 (depends on 24)

The immunogenic composition of claim 24, wherein the inactivated CIV H3N8 is a binary ethyleneimine-inactivated CIV H3N8.

### Claim 28 (depends on 24)

A vaccine comprising the immunogenic composition of claim 24.

### Claim 29 (depends on 28)

The vaccine of claim 28 further comprising an immunologically effective amount of one or more additional inactivated CIV serotypes.

### Claim 30 (depends on 28)

The vaccine of claim 28, further comprising an additional pathogen, wherein the additional pathogen is selected from the group consisting of canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus, canine coronavirus, Leptospira serovars, Leishmania organisms, a Borrolia species (spp.); Bordetella bronchiseptica, Mycoplasma species, rabies virus, Ehrichia canis, and combinations thereof.

### Claim 31 (depends on 28)

The vaccine of claim 28, wherein the CIV H3N8 is formulated at 500 HAU/dose and wherein at least 70% of the HA has the same amino acid sequence.

### Claim 32 (depends on 31)

The vaccine of claim 31, wherein the adjuvant is aluminum hydroxide.

### Claim 33 (depends on 34)

The vaccine of claim 34, wherein at least 90% of the HA has the same amino acid sequence.

### Claim 34 (depends on 28)

A method of immunizing a canine against CIV comprising injecting the canine with the vaccine of claim 28.

### Claim 35 (depends on 34)

Serum comprising antibodies that bind to CIV H3N8 obtained from a canine immunized by the method of claim 34
